2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2228

A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Abstract Number: 473

A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
Abstract Number: 848

A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration
Abstract Number: 2811

Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Abstract Number: 2308

Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
Abstract Number: 1105

Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Abstract Number: 900

Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Abstract Number: 2554

Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Abstract Number: 1266

ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
Abstract Number: 1766

Abdominal Adipose Tissue Predicts Incident Major Cardiovascular Events in Systemic Necrotizing Vasculitis Patients: Data from a Prospective Cohort Study on 120 Patients
Abstract Number: 1906

Abdominal Obesity and Risk of Developing Rheumatoid Arthritis in Women
Abstract Number: 2064

Aberrant Distribution and Function of Plasmacytoid Dendritic Cells in Patients with Ankylosing Spondylitis Are Associated with Unfolded Protein Response
Abstract Number: 1999

Aberrant Expression of the GluN2B N-Methyl D-Aspartate Receptor Subunit in Osteoarthritic Chondrocytes Causes Disease-Associated Changes in Chondrocyte Phenotype through Altered Expression of Core Components of the Chondrocyte Circadian Clock
Abstract Number: 1032

Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 1333

Abnormal Function of High Density Lipoproteins in Idiopathic Inflammatory Myopathies

« Previous Page
1
…
5
6
7
8
9
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].